---
title: "Lonvoguran ziclumeran (lonvo-z): Hereditary angioedema"
description: "Formulary evidence on Lonvoguran ziclumeran (lonvo-z, NTLA-2002) in Hereditary angioedema. Clinical evidence covers HAELO, ITL-2002-CL-001, LTFU, HELP, OASIS-HAE, VANGUARD, and 2 further headings. 213 evidence topics quoted from 82 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Lonvoguran ziclumeran (lonvo-z): Hereditary angioedema

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Lonvoguran ziclumeran

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Hereditary angioedema

<a id="topic-1.1.1-1"></a>

##### Summary

Hereditary angioedema is estimated to affect 1 in 50,000 people worldwide. Symptoms commonly begin in childhood and worsen during puberty. Intestinal attacks cause abdominal symptoms, and airway swelling can be life-threatening. A systematic review reported mean or median diagnostic delays ranging from 3.9 to 26 years. A multinational adult survey reported a mean of 11.5 attacks during the preceding six months, with a standard deviation of 14.2. These findings describe different populations and should not be treated as estimates from one cohort.

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/); [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z); [Watt et al. (2026)](https://link.springer.com/article/10.1186/s13023-025-04134-z)

<a id="heading-1.1.2"></a>

#### 1.1.2 Lonvoguran ziclumeran Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary

In HAELO, the lonvo-z and placebo groups included 52 and 28 participants, respectively. During weeks 5–28, mean monthly attack rates were 0.26 and 2.10, corresponding to an 87% reduction with lonvo-z. The proportions without attacks were 62% and 11%. The between-group difference in change in AE-QoL score was -17.04 points. Through week 28, infusion-related reactions occurred in 32 of 52 participants (62%) receiving lonvo-z and 5 of 28 (18%) receiving placebo. No serious treatment-emergent adverse events or events of grade 3 or higher were reported in the lonvo-z group during that period.

Source: [Intellia Therapeutics HAELO phase 3 results announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-positive-phase-3-results); [Intellia Therapeutics HAELO topline data presentation (2026)](https://ir.intelliatx.com/static-files/d76952d4-4a66-4ab1-b38d-4856721edea3); [Intellia Therapeutics additional HAELO phase 3 results announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-additional-positive-phase-3); [Intellia Therapeutics EAACI presentation (2026)](https://www.intelliatx.com/wp-content/uploads/HAELO-EAACI-2026-Presentation_FINAL.pdf)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Lonvoguran ziclumeran

No evidence found.

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

HAELO provides evidence of reduced attack frequency compared with placebo. The reported median follow-up of 7.5 months does not establish lifetime durability or exclude uncommon delayed adverse effects. Cross-trial comparisons do not establish comparative effectiveness against active prophylactic treatments. The FDA accepted the BLA for Priority Review with a target action date of March 10, 2027; application acceptance is not marketing approval.

Source: [Intellia Therapeutics HAELO phase 3 results announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-positive-phase-3-results); [Intellia Therapeutics HAELO topline data presentation (2026)](https://ir.intelliatx.com/static-files/d76952d4-4a66-4ab1-b38d-4856721edea3); [Intellia Therapeutics presentation (2026)](https://ir.intelliatx.com/node/12426/html); [Intellia Therapeutics BLA acceptance announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-acceptance-biologics-license)

## Related pages
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Terms and abbreviations](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/terms-and-abbreviations.md)
- [Lonvoguran ziclumeran (lonvo-z): Hereditary angioedema](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/executive-summary.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Product information and disease description](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/product-information-and-disease-description.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Clinical evidence](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/clinical-evidence.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Economic information and modeling report](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/economics) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/economics.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: References](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/references) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/references.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: prevalence by geography](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/prevalence) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/prevalence.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/cost-effectiveness-analyses.md)
